- Home
- GAME vs ACXP Comparison
GAME vs ACXP Comparison
Compare GAME & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | ACXP |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 3.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GAME | ACXP |
|---|---|---|
| Price | $0.39 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $95.50 |
| AVG Volume (30 Days) | ★ 8.4M | 680.8K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $81.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.29 |
| 52 Week High | $2.87 | $8.34 |
Technical Indicators
Market Signals| Indicator | GAME | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 68.27 | 41.51 |
| Support Level | $0.26 | $2.48 |
| Resistance Level | $0.48 | $2.89 |
| Average True Range (ATR) | 0.04 | 0.40 |
| MACD | 0.02 | -0.17 |
| Stochastic Oscillator | 68.77 | 13.06 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.